Senior Regulatory Affairs Specialist

iRhythm Technologies reported second-quarter revenue of $224.2 million, up 20.1% year-on-year and beating analyst estimates of $219.2 million. The medical technology company's non-GAAP profit of $0.58 per share significantly exceeded consensus forecasts. The company attributed the performance to sustained demand for its Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. Operating margin improved to -1.1% from -10% in the prior-year quarter, driven by manufacturing automation and workflow optimisation. iRhythm raised its full-year revenue guidance to $885 million from $880 million. The company plans to leverage its pending VitalConnect acquisition to expand into mobile cardiac telemetry and remote patient monitoring markets.

Following cyberattack recovery, iRhythm announces major acquisition & strong 2Q26 results. iRhythm reports 20% revenue growth, settles Baxter suit, and is set to acquire VitalConnect for $287.5 million. Omar Ford, Editor-in-Chief, MD+DI, Informa Markets - Engineering August 7, 2026 There was a lot to digest in iRhythm Technologies' 2Q26 earnings. Revenue was up by 20.1% year-over-year; the company resolved litigation with Baxter; and provided an update on its recovery from a cyberattack in June. But the biggest news from the firm's earnings call was its plan to acquire VitalConnect for $237.5 million in cash and about $50 million in iRhythm common stock. The deal is set to close by the end of the year. San Jose, CA-based VitalConnect is a private wearable biosensor technology company with a strong focus on the mobile cardiac telemetry (MCT) market. It operates an FDA-cleared platform that spans multiple cardiac monitoring modalities and multi-vitals monitoring capabilities designed for hospital and remote care settings. The company's biosensor platform can monitor up to 11 physiological parameters. "The strategic fit is compelling," said Quentin Blackford, president and CEO of iRhythm, according to a Seeking Alpha transcript of the earnings call. "Vital Connect reinforces our commitment to innovation in ambulatory cardiac monitoring and adds an FDA-cleared platform with a patient monitoring service up to 30 days, 4-in-1 device functionality, flexible service models, live-looking capabilities, and multivital monitoring." According to the Seeking Alpha transcript, he added, "These features complement our existing portfolio and give us additional tools to meet different clinical, operational, and economic needs of customers and patients. This acquisition also expands our ability to participate in the MCT segment." The company said it expects the acquisition to positively contribute to revenue growth beginning in 2027. iRhythm executives noted Vital Connect is currently at an approximately $65 million annual revenue run rate. "By combining our flexible biosensor platform, AI-enabled algorithms and streamlined workflows with iRhythm's commercial scale and reach, we intend to bring a more compelling portfolio to a larger base of customers and patients than either company could deliver independently," Peter Van Haur, CEO of VitalConnect Together, MD+DI expect to unlock new growth opportunities across ambulatory cardiac monitoring, inpatient monitoring and hospital-to-home care." BTIG analysts sound off on iRhythm's acquisition. Marie Thibault, an analyst with BTIG, wrote the deal was surprising and offered commentary on how investors might view the acquisition. "We expect investor views of the deal to be mixed, with the obvious concern being that this might be an attempt to disguise an underlying slowdown in the MCT segment," she wrote in a research note. "There may also be some concern about iRhythm's ability to sell two products simultaneously in the MCT market or whether the Zio MCT product is underwhelming. We acknowledge these issues but also believe iRhythm had previously appraised and liked the technology and that timing of the deal may be down to opportunity matched with VitalConnect's capital needs timeline." News of the pending acquisition and the 2Q26 earnings helped boost iRhythm's shares up by more than 2% in after-hours trading. iRhythm's cyberattack recovery. The deal comes nearly two months after the firm announced it received a notice from a "threat actor" that it had obtained protected patient information, including proprietary data, patient protected health information, and other personal information. The cyberterror organization demanded payment from iRhythm in exchange for not leaking the data. The company confirmed that the cyberterror group did obtain sensitive information. "The incident has been contained and the root cause identified," Blackford said, according to a Seeking Alpha transcript of the call. "While certain data was exfiltrated, our investigation and remediation actions resulted in no material impacts to our products, patient care, business operations or financial results." Editor-in-Chief, MD+DI, Informa Markets - Engineering Omar Ford is a seasoned journalist specializing in medical technology, healthcare innovation, and the medical device and diagnostics industry. As the editor-in-chief of Medical Device + Diagnostics Industry (MD+DI), he has earned a reputation as a leading authority in the field, offering in-depth insights into the latest trends, regulatory changes, and technological advancements shaping the future of healthcare. Omar has been a featured speaker at MD&M and MEDevice events. Omar has written for several publications prior to MD+DI. He is a former contributor at Bioworld Medtech, an online publication owned by Clarivate. He was a general assignment reporter for the Beaufort Gazette and an education and county reporter for the Griffin Daily News. He is the 2001 winner of the Judson Chapman Award from the South Carolina Press Association and the 2003 McClatchy President's Award recipient. Omar has a bachelor's degree in print journalism from the University of South Carolina. Throughout his tenure at MD+DI, Omar has covered a wide array of topics, including medical technology innovations, regulatory affairs, market dynamics, and the growing impact of artificial intelligence in healthcare. Omar is the host of the Let's Talk Medtech podcast. Want more MD+DI in your search results?

iRhythm Technologies reported second-quarter revenue of $224.2 million, beating analyst estimates of $219.2 million and representing 20.1% year-on-year growth. The medical technology company, which provides wearable cardiac monitoring devices and AI-powered analysis services, also exceeded profit expectations with non-GAAP earnings of $0.58 per share. The company raised its full-year revenue guidance to $885 million from $880 million, aligning closely with analyst forecasts. Operating margin improved to -1.1%, up from -10% in the same quarter last year. Chief Executive Quentin Blackford attributed the results to strong execution and progress against strategic priorities. Analysts project 14.7% revenue growth over the next 12 months.